1Faubion WA Jr, I.oftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology, 2001,121:255-260.
2Stange EF, TravisSP, VermeireS, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut, 2006, 55 (Suppl 1): i1-i15.
3Stange EF, Travis SPI., Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis Colitis, 2008, 2:1-23.
4Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am, 2004, 33:319-334.
5Kane S, Huo D, Aikens J. et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med, 2003, 114:39-43.
6Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis, 2003, 9:205-209.
7Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut, 2006, 55:47-53.
8Mahadevan U, Sandborn WJ. Clinical pharmacology of inflammatory bowel disease therapy// Sartor RB, Sandborn WJ. Kirsner's Inflammatory Bowel Diseases. 61h ed. New York, Saunders USA, 2004: 488-490.
9Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6- mercaptopurine therapy in inflammatory bowel disease.Gastroenterology, 2000, 118: 705-713.
10Duley JA, Florin TH. Azathioprine: when less is more. J Gastroenterol Hepathol, 2008, 23: 1317-1319.
